Cargando…
Ganglionated Plexi Ablation for the Treatment of Atrial Fibrillation
Atrial fibrillation (AF) is the most common type of cardiac arrhythmia and is associated with significant morbidity and mortality. The autonomic nervous system (ANS) plays an important role in the initiation and development of AF, causing alterations in atrial structure and electrophysiological defe...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598705/ https://www.ncbi.nlm.nih.gov/pubmed/32987820 http://dx.doi.org/10.3390/jcm9103081 |
_version_ | 1783602689240727552 |
---|---|
author | Avazzadeh, Sahar McBride, Shauna O’Brien, Barry Coffey, Ken Elahi, Adnan O’Halloran, Martin Soo, Alan Quinlan, Leo. R |
author_facet | Avazzadeh, Sahar McBride, Shauna O’Brien, Barry Coffey, Ken Elahi, Adnan O’Halloran, Martin Soo, Alan Quinlan, Leo. R |
author_sort | Avazzadeh, Sahar |
collection | PubMed |
description | Atrial fibrillation (AF) is the most common type of cardiac arrhythmia and is associated with significant morbidity and mortality. The autonomic nervous system (ANS) plays an important role in the initiation and development of AF, causing alterations in atrial structure and electrophysiological defects. The intrinsic ANS of the heart consists of multiple ganglionated plexi (GP), commonly nestled in epicardial fat pads. These GPs contain both parasympathetic and sympathetic afferent and efferent neuronal circuits that control the electrophysiological properties of the myocardium. Pulmonary vein isolation and other cardiac catheter ablation targets including GP ablation can disrupt the fibers connecting GPs or directly damage the GPs, mediating the benefits of the ablation procedure. Ablation of GPs has been evaluated over the past decade as an adjunctive procedure for the treatment of patients suffering from AF. The success rate of GP ablation is strongly associated with specific ablation sites, surgical techniques, localization techniques, method of access and the incorporation of additional interventions. In this review, we present the current data on the clinical utility of GP ablation and its significance in AF elimination and the restoration of normal sinus rhythm in humans. |
format | Online Article Text |
id | pubmed-7598705 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75987052020-10-31 Ganglionated Plexi Ablation for the Treatment of Atrial Fibrillation Avazzadeh, Sahar McBride, Shauna O’Brien, Barry Coffey, Ken Elahi, Adnan O’Halloran, Martin Soo, Alan Quinlan, Leo. R J Clin Med Review Atrial fibrillation (AF) is the most common type of cardiac arrhythmia and is associated with significant morbidity and mortality. The autonomic nervous system (ANS) plays an important role in the initiation and development of AF, causing alterations in atrial structure and electrophysiological defects. The intrinsic ANS of the heart consists of multiple ganglionated plexi (GP), commonly nestled in epicardial fat pads. These GPs contain both parasympathetic and sympathetic afferent and efferent neuronal circuits that control the electrophysiological properties of the myocardium. Pulmonary vein isolation and other cardiac catheter ablation targets including GP ablation can disrupt the fibers connecting GPs or directly damage the GPs, mediating the benefits of the ablation procedure. Ablation of GPs has been evaluated over the past decade as an adjunctive procedure for the treatment of patients suffering from AF. The success rate of GP ablation is strongly associated with specific ablation sites, surgical techniques, localization techniques, method of access and the incorporation of additional interventions. In this review, we present the current data on the clinical utility of GP ablation and its significance in AF elimination and the restoration of normal sinus rhythm in humans. MDPI 2020-09-24 /pmc/articles/PMC7598705/ /pubmed/32987820 http://dx.doi.org/10.3390/jcm9103081 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Avazzadeh, Sahar McBride, Shauna O’Brien, Barry Coffey, Ken Elahi, Adnan O’Halloran, Martin Soo, Alan Quinlan, Leo. R Ganglionated Plexi Ablation for the Treatment of Atrial Fibrillation |
title | Ganglionated Plexi Ablation for the Treatment of Atrial Fibrillation |
title_full | Ganglionated Plexi Ablation for the Treatment of Atrial Fibrillation |
title_fullStr | Ganglionated Plexi Ablation for the Treatment of Atrial Fibrillation |
title_full_unstemmed | Ganglionated Plexi Ablation for the Treatment of Atrial Fibrillation |
title_short | Ganglionated Plexi Ablation for the Treatment of Atrial Fibrillation |
title_sort | ganglionated plexi ablation for the treatment of atrial fibrillation |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598705/ https://www.ncbi.nlm.nih.gov/pubmed/32987820 http://dx.doi.org/10.3390/jcm9103081 |
work_keys_str_mv | AT avazzadehsahar ganglionatedplexiablationforthetreatmentofatrialfibrillation AT mcbrideshauna ganglionatedplexiablationforthetreatmentofatrialfibrillation AT obrienbarry ganglionatedplexiablationforthetreatmentofatrialfibrillation AT coffeyken ganglionatedplexiablationforthetreatmentofatrialfibrillation AT elahiadnan ganglionatedplexiablationforthetreatmentofatrialfibrillation AT ohalloranmartin ganglionatedplexiablationforthetreatmentofatrialfibrillation AT sooalan ganglionatedplexiablationforthetreatmentofatrialfibrillation AT quinlanleor ganglionatedplexiablationforthetreatmentofatrialfibrillation |